治験一覧
8,963 件中 5821〜5840 件を表示
NLAツールの実現可能性に関する臨床研究
The study is to evaluate the feasibility of the NLA tool, a combined assessment of nutritional and physical functional status, to provide personalized advice for the independence and mobility of elderly.
視神経脊髄炎（NMO）および視神経脊髄炎スペクトラム障害（NMOSD）患者に対するサトラリズマブ（SA237）の併用療法としての有効性および安全性に関する研究
The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in participants with NMO and NMOSD.
急性胆嚢炎に対するEGBDとPCのランダム化比較試験。
Acute cholecystitis commonly occurs in elderly patients that are high-risk candidates for surgery. Percutaneous cholecystostomy (PC) is frequently employed for gallbladder drainage in these patients. Recently, the feasibility of EUS-guided gallbladder drainage (EGBD) in treatment of this condition has been demonstrated but how the two procedures compare to one another is uncertain. The aim of this study is to compare EGBD versus PC as a definitive treatment, in high-risk patients suffering from acute cholecystitis in a randomized controlled trial. We hypothesize that EGBD can reduce the morbidity, re-intervention and mortality when compared to PC.
RSV感染で入院した乳児におけるALS-008176の研究
This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single and multiple doses of ALS-008176 in infants hospitalized with respiratory syncytial virus (RSV)
血液透析を受けている慢性腎臓病（CKD）患者におけるエポエチンアルファ／ベータ療法とBAY85-3934療法による慢性腎臓病に伴う貧血の維持療法の比較
Evaluate efficacy and safety of 16 weeks of titrated dose treatment with BAY85-3934 versus epoetin alfa/beta as measured by hemoglobin (Hb) levels. Fixed starting doses of 25, 50,75 and 150 mg of BAY85-3934 titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg/day
腹膜透析を受けている患者における二次性副甲状腺機能亢進症に対するKHK7580の研究
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.
慢性腎臓病に伴う貧血を有する日本人血液透析患者におけるGSK1278863の安全性、有効性および薬物動態を評価する研究
This study aims to characterize the relationship between dose of GSK1278863 and hemoglobin (Hgb) response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease (CKD). It is anticipated that the data generated will enable selection of the starting dose(s) and optimize dose adjustment regimen(s) for Phase 3 clinical trials. This study will consist of a screening phase of 3-9 weeks, a 4-week treatment phase and a follow-up visit approximately 4 weeks after completing treatment.
統合失調症患者における三角筋への反復注射によるアリピプラゾールIMデポ製剤（OPC-14597 IMD）投与時の薬物動態および安全性を検討する多施設共同非盲検試験
To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
口臭を軽減するための口腔衛生手順
The purpose of the study is to evaluate the effect of various oral hygiene procedures on reduction of oral malodor.
ファブリー病患者におけるミガラスタット塩酸塩の長期効果に関する非盲検延長試験
This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.
リセドロン酸ナトリウム錠 - 骨パジェット病患者における特別な薬剤使用監視（全症例監視） - 48週間監視 -
The purpose of this study is to evaluate the safety and efficacy of sodium risedronate tablets administered once daily (one tablet per dose) in patients with osseous Paget's disease for 48 weeks from baseline in daily medical practice.
非小細胞肺癌（NSCLC）患者におけるMEDI4736（抗PD-L1抗体）とゲフィチニブの併用療法。
This a Phase I, Open-Label, Multicentre Study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of gefitinib in combination with MEDI4736 (anti PD-L1) in Subjects with Non-small cell lung cancer (NSCLC). The study consists of two phases: Escalation phase and an expansion phase to be conducted in locally advanced or metastatic NSCLC subjects
アルツハイマー病による軽度認知障害および軽度アルツハイマー病患者を対象とした、BAN2401の反復静脈内投与の安全性、忍容性、薬物動態、免疫原性、および薬力学的反応を評価するための無作為化二重盲検プラセボ対照試験
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in subjects with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.
銀フレックスの日本における市販後調査
Japanese post market clinical study of the Zilver Flex device.
中等度から重度の潰瘍性大腸炎の小児患者におけるアダリムマブの有効性と安全性
The purpose of the study is to demonstrate the efficacy and safety, and to assess the pharmacokinetics of adalimumab administered subcutaneously (SC) in pediatric subjects with moderate to severe ulcerative colitis (UC).
TP53wt遺伝子変異を有する特定の進行性腫瘍患者におけるHDM201の安全かつ忍容性の高い投与量を決定および評価するための研究
To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.
デスフルラン誘発性心筋保護
This study examines pharmacological preconditioning and post conditioning of desflurane by comparing cardiac troponin release in patients receiving either desflurane or propofol for the aortic valve surgery.
喘息におけるモンテルカストの気道制御性T細胞への影響
Montelukast is one of anti-inflammatory agents and a good controller for the patients with asthma. The hypothesis of the study is that the Montelukast will have airway anti-inflammatory effects and up-regulated regulatory T cells functions in asthma.
日本における慢性変形性関節症および膝痛患者を対象としたデュロキセチン（LY248686）の臨床試験
The main purpose of this study is to evaluate the efficacy of the study drug known as duloxetine in participants with chronic osteoarthritis (OA) and knee pain in Japan.
近視性脈絡膜新生血管に対するEYLEAの特別薬物使用調査
The objectives of this study are to investigate the safety and effectiveness of EYLEA.